Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.
FDA panel endorses Novartis psoriasis drug; court rules with Pfizer on cancer drug patent; drugmakers may look for indemnity against losses from Ebola vaccines.
GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.
The Post X-er, Post-Boomer generation considers traditional healthcare "sick care."
Shire bows out of AbbVie acquisition; CVS's PBM will charge premium for consumers who fill scripts at tobacco-selling pharmacies; Reckitt Beckinser will rebrand following demerger.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.